800402-12-4

Basic information

• Product Name: 2-Chloro-5-iodo-4-pyridinamine
• Synonyms: 2-Chloro-5-iodo-4-pyridinamine;4-Amino-2-chloro-5-iodopyridine;4-Amino-5-iodo-2-chloropyridine;2-Chloro-5-iodo-pyridin-4-ylamine
• CAS NO: 800402-12-4
• Molecular Formula: C₅H₄ClIN₂
• Molecular Weight: 254.454
• Mol File: 800402-12-4.mol
• Article Data: 32

Chemical Properties

• Melting Point: 126-127°
• Boiling Point: 367.751°C at 760 mmHg
• Flash Point: 176.21°C
• Appearance: /
• Density: 2.139g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.708
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.96±0.42(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 2-Chloro-5-iodo-4-pyridinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-iodo-4-pyridinamine(800402-12-4)
• EPA Substance Registry System: 2-Chloro-5-iodo-4-pyridinamine(800402-12-4)

Safety Data

• Hazard Codes: Xi
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 800402-12-4(Hazardous Substances Data)

Usage

General Description

2-Chloro-5-iodo-4-pyridinamine is a chemical compound that has the molecular formula C5H3ClIN3. It is a derivative of pyridine and contains both chlorine and iodine atoms. 2-Chloro-5-iodo-4-pyridinamine is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. It has also found applications in the field of medicinal and agrochemical research. The presence of halogen substituents in its structure makes it a valuable building block for the development of new chemical entities with potential biological activities. Additionally, 2-Chloro-5-iodo-4-pyridinamine is known for its reactivity and can undergo various chemical transformations under suitable reaction conditions.

InChI:InChI=1/C5H4ClIN2/c6-5-1-4(8)3(7)2-9-5/h1-2H,(H2,8,9)

Upstream product

• 14432-12-3 4-Amino-2-chloropyridine 
• 657408-07-6 dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane 
• 1251041-55-0 3-chlorobenzofuran[3,2-c]pyridine 
• 98-80-6 phenylboronic acid 

Downstream Products

• 800401-54-1 6-chloro-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid 
• 1400287-02-6 tert-butyl 4-(6-(4-fluorophenylamino)-1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)-1H-pyrazole-1-carboxylate 
• 1400286-48-7 N-(4-fluorophenyl)-1-(methylsulfonyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine 
• 1400286-49-8 N-(4-fluorophenyl)-2-(1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-amine 
• 1400286-76-1 tert-butyl 2-(1-(tert-butoxycarbonyl)-1H-pyrazol-4-yl)-6-(p-tolylamino)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400286-98-7 tert-butyl 2-(1-(tert-butoxycarbonyl)-1H-pyrazol-4-yl)-6-(4-(dimethylcarbamoyl)phenylamino)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1600524-53-5 1-(3,4-diamino-5-(3-fluorophenyl)pyridin-2-yl)piperidine-3-carboxamide 
• 1600524-50-2 1-(4-amino-5-(3-fluorophenyl)-3-nitropyridin-2-yl)piperidine-3-carboxamide 
• 1600524-52-4 1-(4-amino-5-(4-fluoro-3-methoxyphenyl)-3-nitropyridin-2-yl)piperidine-4-carboxamide 
• 1600524-55-7 1-(3,4-diamino-5-(4-fluoro-3-methoxyphenyl)pyridin-2-yl)piperidine-4-carboxamide 
• 1600524-65-9 1-(2-(2,4-dichlorobenzyl)-7-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-4-yl)piperidine-4-carbonitrile 
• 1600524-66-0 1-(7-(1-methyl-1H-pyrazol-4-yl)-2-phenethyl-1H-imidazo[4,5-c]pyridin-4-yl)piperidine-4-carbonitrile 
• 1600524-67-1 1-(2-(2,4-dichlorobenzyl)-7-(4-fluoro-3-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-4-yl)piperidine-4-carbonitrile 

Relevant articles and documents

Organic compound, electroluminescent device containing organic compound and applications of electroluminescent device

The invention discloses an organic compound with a structure represented by a formula (I), wherein the LUMO energy level of the compound is reduced by linking an aza aromatic ring structure (a structure represented by a formula (II)), so that the electronic conductivity of the material is improved, and the compound is suitable for being used as an electronic material (such as an electron transportmaterial, an electron injection material, a hole blocking material and the like). According to the invention, the organic compound as an electron type material, particularly an electron transmissionmaterial, can be matched with hole type materials (such as a hole transmission material, a hole injection material and an electron blocking material), so that the transmission of electrons and holes is balanced, and the service life of a device is prolonged.

Synthesis, molecular docking, antimycobacterial and antimicrobial evaluation of new pyrrolo[3,2-c]pyridine Mannich bases

In this report, we describe the synthesis and biological evaluation of a new series of pyrrolo[3,2-c]pyridine Mannich bases (7a-v). The Mannich bases were obtained in good yields by one-pot three component condensation of pyrrolo[3,2-c]pyridine scaffold (6a-c) with secondary amines and excess of formaldehyde solution in AcOH. The chemical structures of the compounds were characterized by 1H NMR, 13C NMR, LC/MS and elemental analysis. Single crystal X-ray diffraction has been recorded for compound 7k ([C23H29ClN4]+2, H2O). The in?vitro antimicrobial activities of the compounds were evaluated against various bacterial and fungal strains using Agar diffusion method and Broth micro dilution method. Compounds 7e, 7f, 7r, 7t, and 7u were showed good Gram-positive antibacterial activity against S.?aureus, B. flexus, C. sporogenes and S. mutans. Furthermore, in?vitro antimycobacterial activity was evaluated against Mycobacterium tuberculosis H37Rv (ATCC 27294) using MABA. Compounds 7r, 7t, and 7u were showed good antitubercular activity against Mtb (MIC ≥6.25?μg/mL). Among the tested compounds, 1-((4-chloro-2-(cyclohexylmethyl)-1H-pyrrolo[3,2-c]pyridin-3-yl)methyl)piperidine-3-carboxamide (7t) was showed excellent antimycobacterial activity against Mtb (MIC >25). Molecular docking of the active compounds against glutamate racemase (MurI) and Mtb glutamine synthetase were explained the structure-activity observed in?vitro.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)

Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to give an integrated assessment of compound selectivity during optimization resulting in a highly CHK1 selective adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector directed away from the CHK1 kinase active site was unexpectedly found to drive the selective cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic-pharmacodynamic (PK-PD) properties gave a compound with low predicted doses and exposures in humans which mitigated the residual weak in vitro hERG inhibition.